High-load actives
in confectionery systems.
When active load increases, the matrix must evolve. Otherwise, you don't have a formulation. You have a delayed failure — one that shows up six months after launch when consumers start returning soft packs with crystallized centres.
200 mg worked. 400 mg didn't.
A Bengaluru nutraceutical brand wanted to double the active load in their vitamin D3+K2 gummy — from 200 mg per serving to 400 mg — after consumer research showed the existing dose wasn't landing in clinical outcome ranges. Their existing manufacturer could hit the dose, but at 400 mg the gummy base started syneresis: weeping liquid at room temperature.
The manufacturer's fix was to reduce the gelatin ratio. That stopped the weeping — but created a new problem: the gummy became too rigid and the active started migrating to the centre during cool-down, creating a crystallized core. This is the textbook delayed failure. It wouldn't show up in a 7-day QC cycle. It showed up at month six on shelves.
The matrix must evolve with the load.
Increasing the active concentration changes the rheological behavior of the entire gummy matrix. The plasticizer ratio, setting temperature, and co-gelling agent all need to be recalculated simultaneously — not sequentially. Bettrlabs' formulation agents ran a matrix redesign that treated active load as the independent variable and co-optimized everything else.
Rheology modelling
Active load × gelatin ratio × pectin co-gel mapped across 12 viscosity target bands.
Thermal profile
Setting temperature and cool-down gradient recalculated to prevent active migration.
Stability simulation
12-month shelf model at 25°C/60% RH and 40°C/75% RH — no syneresis, no crystallization.
Every dose change
is a new formulation.
"When active load increases, the matrix must evolve. Otherwise, you don't have a formulation. You have a delayed failure."
This is the most common expensive mistake in nutraceutical D2C: a brand iterates on dose without treating the dose change as a full reformulation event. The base looks fine at QC. It fails six months later. The warranty claims arrive before the root cause analysis does.
Bettrlabs treats every active load change as a matrix trigger. Any dose delta above 15% auto-flags a full rheology re-run before the compliance submission goes out.
400 mg. Clean shelf. Zero returns.
"We'd been told doubling the dose would cost us 35% more on COGS. Bettrlabs came back with a matrix design that hit 400 mg at 22% lower cost than our original 200 mg formulation — and it hasn't failed on shelf once. We've shipped 3 batches."
Design it right
the first time.
Your first Quick Check is free — same-day Brand Fit Score, regulatory traffic light, and indicative cost band.